



New Drugs Reviewed by CPG January 23, 2017
 (Original New Drug Applications: FDA)

Generic Name	Trade Name	Indication(s)	CPG Action
Immune globulin subcutaneous [human] 20% solution	Cuvitru	<i>Biologic and Immunological Agents/Immune Globulins/ Immune Globulin (Human) subcutaneous.</i> Indicated as replacement for primary humoral immunodeficiency in adult and pediatric patients age two and older.	In accordance with the SCA
eteplirsen	Exondys 51	<i>Central Nervous System Agents/Antisense Oligonucleotides.</i> Treatment of patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping. First drug approved for treatment of patients with Duchenne muscular dystrophy.	In accordance with the SCA
levonorgestrel-releasing intrauterine system 19.5 mg	Kyleena	<i>Endocrine and Metabolic Agents/sex hormones/contraceptive Hormones.</i> Prevention of pregnancy for up to five years.	May prescribe
**Phentermine hydrochloride 8 mg **(new formulation at lower dosage)	Lomaira	<i>Central Nervous System Agents/ anorexiant/sympathomimetic anorexiant.</i> Short term use weight reduction in adults with an initial BMI of 30 or more or 27 with at least one weight-related condition.	In accordance with the SCA

New Drugs January 2017

<p>canagliflozin/ metformin HCL extended-release</p>	<p>Invokamet XR</p>	<p><i>Endocrine and Metabolic Agents/ antidiabetic agents/antidiabetic combination products.</i> Treatment of adults with type 2 diabetes as an adjunct to diet and exercise.</p>	<p>May prescribe</p>
<p>Adalimumab-atto</p>	<p>Amjevita</p>	<p><i>Biologic and Immunological Agents/ Immunologic Agents/Immunomodulators/Tumor necrosis Factor-Alpha Blockers.</i> Indicated for treatment of adults with: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, and plaque psoriasis. Also indicated for juvenile idiopathic arthritis in pts age 4 years and older.</p>	<p>In accordance with the SCA</p>
	<p>Flublok Quadravalent</p>	<p><i>Biologic and Immunological Agents/agents for active immunization/vaccines, viral.</i> Protects against 4 strains of influenza, 3 of the same strains found in trivalent Flublok as well as an additional B strain. Approved for adults age 18 and older.</p>	<p>May prescribe</p>

olaratumab	Lartuvo	<i>Antineoplastic Agents/monoclonal antibodies.</i> For use in combination with doxorubicin for the treatment of adult patients with soft tissue sarcoma with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.	May not prescribe
bezlotoxumab	Zinplava	<i>Biologic and Immunological Agents/ monoclonal antibodies (biologic/immunologic).</i> Reduces recurrence of C-diff infection in patients age 18 and older who are receiving antibacterial drug treatment of C-diff and are at high risk for recurrence.	May prescribe
tenofovir alafenamide	Vemlidy	<i>Anti-infective Agents/ antiretroviral agents/nucleotide analog reverse transcriptase inhibitors.</i> Treatment of chronic hepatitis B infection in adults with compensated liver disease.	May prescribe
DHEA	Intrarosa	<i>Endocrine and Metabolic Agents/ sex hormones.</i> Treatment of postmenopausal moderate to severe dyspareunia.	May prescribe

New Drugs January 2017

Insulin glargine/lixisenatide	Soliqua	<i>Endocrine and Metabolic Agents/antidiabetic agents/insulin combination.</i> Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes inadequately controlled on basal insulin or lixisenatide.	May prescribe
	SMOFlipid	<i>Nutrients and Nutritional Agents/intravenous nutritional therapy/lipids.</i> Source of calories, essential fatty acids, and omega-3 fatty acids for adults requiring parenteral nutrition.	May prescribe
Eucrisa	Crisaborole 2%	<i>Dermatological agents/phosphodiesterase-4 inhibitors.</i> Topical treatment of mild to moderate atopic dermatitis in patients age 2 years and older.	May prescribe
rucaparib	Rubraca	<i>Antineoplastic Agents/PARP Enzymes Inhibitor.</i> Approved for treatment of ovarian cancer.	In accordance with the SCA
nusinersen	Spinraza	<i>Central Nervous System Agents/Antisense Oligonucleotides.</i> Treatment of spinal muscular atrophy.	In accordance with the SCA



New Drug Indications/ Warnings Reviewed by CPG

January 23, 2017

(New Drug Indications/ Boxed Warnings: FDA)

Generic Name	Trade Name	Therapeutic Category	CPG Action
canakinumab (expanded indication)	Ilaris	<i>Biologic and Immunological Agents; immunologic agents; immunomodulators</i>	Current: In accordance with the SCA January 23, 2017: No change
ustekinumab (expanded indication)	Stelara	<i>Biologic and Immunological Agents; immunologic agents; immunomodulators</i>	Current: In accordance with the SCA January 23, 2017: No change
idelalisib (expanded black box warning)	Zydelig	<i>Antineoplastic Agents; Kinase Inhibitors; phosphatidylinositol 3-kinase inhibitors</i>	Current: May not prescribe January 23, 2017: No change
lumacaftor/ ivacaftor (expanded indication)	Orkambi	Endocrine and Metabolic Agents; cystic fibrosis transmembrane regulator protein	Current: In accordance with the SCA January 23, 2017: No change
eltrombopag (expanded boxed warning)	Promacta	<i>Hematologic Agents; hematopoietic agents; thrombopoietin receptor agonist</i>	Current: In accordance with the SCA January 23, 2017: No change
atezolizumab (expanded indication)	Tecentriq	Antineoplastic agents; monoclonal antibodies (antineoplastic)	Current: May not prescribe January 23, 2017: No change
paricalcitol (expanded indication)	Zemlar	<i>Nutrients and Nutritional Agents; vitamins; fat-soluble vitamins; vitamin D</i>	Current: May prescribe January 23, 2017: No change

New Drug Indications January 2017

pembrolizumab (expanded indication)	Keytruda	<i>Biologic and Immunological Agents; immunologic agents; immunomodulators</i>	Current: May not prescribe January 23, 2017: No change
etanercept (expanded indication)	Enbrel	<i>Biologic and Immunological Agents; immunologic agents; immunomodulators; tumor necrosis factor-alpha blockers (TNF-alpha blockers)</i>	Current: In accordance with the SCA January 23, 2017: No change
daratumumab (expanded indication)	Darzalex	<i>Antineoplastic Agents; monoclonal antibodies (antineoplastic)</i>	Current: May not prescribe January 23, 2017: No change
flu vaccine (expanded indication)	FluLaval Quadrivalent	<i>Biologic and Immunological Agents/ Agents for Active Immunization/vaccine, viral.</i>	Current: May prescribe January 23, 2017: No change
sevelamer carbonate (expanded indication)	Renvela	<i>Renal and Genitourinary Agents/ Phosphate Binders.</i>	Current: May prescribe January 23, 2017: No change
empagliflozin (expanded indication)	Jardiance	<i>Endocrine and Metabolic Agents/ Antidiabetic Agents/ sodium-glucose co-transporter 2 inhibitors.</i>	Current: May prescribe January 23, 2017: No change
hyaluronic acid (expanded indication)	Restylane Refyne	<i>Central Nervous System Agents/ physical adjuncts/hyaluronic acid derivatives, dermal.</i>	Current: May prescribe January 23, 2017: No change
hyaluronic Acid (expanded indication)	Restylane Defyne	<i>Central Nervous System Agents/ physical adjuncts/hyaluronic acid derivatives, dermal.</i>	Current: May prescribe January 23, 2017: No change
degludec and degludec/insulin aspart (expanded indication)	Tresiba and Ryzodeg 70/30	<i>Endocrine and Metabolic Agents/ Antidiabetic Agents/Insulin.</i>	Current: May prescribe January 23, 2017: No change

New Drug Indications January 2017

chlorazepate dipotassium (boxed warning)	Tranxene T-Tab	<i>Central Nervous System Agents/ Benzodiazepines.</i>	Current: may prescribe January 23, 2017: No change
temazepam (boxed warning)	Restoril	<i>Central Nervous System Agents/ Benzodiazepines.</i>	Current: May prescribe January 23, 2017: No change
tramadol hydrochloride (boxed warning)	Utram	<i>Central Nervous System Agents/ Opioid Analgesics.</i>	Current: May prescribe January 23, 2017: No change
antihemophilic factor [recombinant], pegolated (expanded indication)	Adynovate	<i>Hematological Agents/Antihemophilic Agents/Antihemophilic Factor (Factor VIII:AHF).</i>	Current: In accordance with the SCA January 23, 2017: No change
nalbuphine hydrochloride (boxed warning)	Nubain	<i>Central Nervous System Agents/ Opioid Agonist-Antagonist Analgesics.</i>	Current: May prescribe January 23, 2017: No change
Diazepam (boxed warning)	Valium	<i>Central Nervous System Agents/ Benzodiazepines.</i>	Current: May prescribe January 23, 2017: No change
oxymorphone hydrochloride (expanded indication)	Opana	<i>Central Nervous System Agents/Opioid Analgesics.</i>	Current: Subject to Schedule II restrictions/formulary January 23, 2017: No change
fentanyl citrate (boxed warning)	Fentanyl	<i>Central Nervous System Agents/Opioid Analgesics.</i>	Current: Subject to Scheduel II restrictions/formulary January 23, 2017: No change
pentazocine (boxed warning)	Talwin	<i>Central Nervous System Agents/ Opioid Agonist-Antagonist Analgesics.</i>	Current: May prescribe January 23, 2017: No change

New Drug Indications January 2017

Merperidine hydrochloride (boxed warning)	Demerol	<i>Central Nervous System Agents/ Opioid Analgesics.</i>	Current: subject to Schedule II prescribing restrictions/ formulary January 23, 2017: No change
chlordizepoxide hydrochloride (boxed warning)	Librium	<i>Central Nervous System Agents/ Benzodiazepines.</i>	Current: May prescribe January 23, 2017: No change
empaglifozin/ Linagliptin (expanded indication)	Glyxambi	<i>Endocrine and Metabolic Agents/ Antidiabetic Agents/ Antidiabetic Combination products.</i>	Current: May prescribe January 23, 2017: No change
Sufentanil citrate (boxed warning)		<i>Central Nervous System Agents/Opioid Analgesics.</i>	Current: subject to schedule II prescribing restrictions/ formulary January 23, 2017: No change
oxycodone hydrochloride/ aspirin (boxed warning)	Percodan	<i>Central Nervous System Agents/Opioid Analgesic Combinations.</i>	Current: subject to schedule II prescribing restrictions/ formulary January 23, 2017: No change
ranibizumab (expanded indication)	Lucentis	<i>Ophthalmic and Otic Agents/ Selective Vascular Endothelial Growth Factor Antagonists.</i>	Current: In accordance with the SCA January 23, 2017: No change



Formulary Revision Request January 23, 2017

Generic Name	Trade Name	Indication(s)	CPG Action
Formulary Review Revision Requests from Beth Faiman et al, Cleveland Clinic Taussig Cancer Institute			
(subcategories within Antineoplastic Section) Kinase inhibitors Proteasome Inhibitors Monoclonal antibodies Alkalating Agents	multiple		CPG comprehensively reviewed individual drugs within the Anti-neoplastic Section of the Formulary. See CPG Updates for prescribing parameter change for specific drugs.
Antimetabolite and substituted ureas	multiple		CPG comprehensively reviewed individual drugs within the Anti-neoplastic Section of the Formulary. See CPG Updates for prescribing parameter change for specific drugs.
Formulary Review Revision Request from Cindy Tudor, Cincinnati Children's Hospital Medical Center			
Vigabatrin (REMS Program)	Sabril	Central Nervous System Agents: Anticonvulsants Infantile spasms: As monotherapy for pediatric patients 1 month to 2 years of age with infantile spasms for whom the potential benefits outweigh the potential risk of vision loss. Refractory complex partial seizures: As	Current: CTP holder may not prescribe January 23, 2017: In accordance with the SCA

		adjunctive therapy for adults and pediatric patients 10 years and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss. ¹	
--	--	---	--



Review of Prescribing Designations In Accordance with Standard Care Arrangement and CTP Holder May NOT Prescribe

Antineoplastic Agents (January 23, 2017)

Drug Name	Antineoplastic Subcategory	Current Prescribing Designation	CPG Action
Busulfan	Alkylating Agents/ Alkyl Sulfonates	May not prescribe	January 23, 2017: No change
Estramustine Phosphate Sodium	Alkylating Agents/ Estrogen/Nitrogen Mustard	May not prescribe	January 23, 2017: No change
Altretamine (Hexamethylmelamine)	Alkylating Agents/ Ethylenimines/Methylmelamines	May not prescribe	January 23, 2017: No change
Thiotepa (Triethylenethiophosphoramidate ; Tspa; Tespa)	Alkylating Agents/ Mechlorethamine Derivative	May not prescribe	January 23, 2017: No change
Altretamine (Hexamethylmelamine)	Alkylating Agents/ Ethylenimines/Methylmelamines	May not prescribe	January 23, 2017: No change
Bendamustine Hydrochloride	Alkylating Agents/ Ethylenimines/Methylmelamine/ Mechlorethamine Derivative	May not prescribe	January 23, 2017: No change
Thiotepa (Triethylenethiophosphoramidate ; Tspa; Tespa)	Alkylating Agents Ethylenimines/Methylmelamines	May not prescribe	January 23, 2017: No change
Chlorambucil	Alkylating Agents/ Nitrogen Mustards	May not prescribe	January 23, 2017: No change
Cyclophosphamide	Alkylating Agents/ Nitrogen Mustards/ Cyclophosphamide	May not prescribe	January 23, 2017: No change
Ifosfamide	Alkylating Agents/ Nitrogen Mustards	May not prescribe	January 23, 2017: No change
Mechlorethamine Hydrochloride	Alkylating Agents/ Nitrogen Mustards/ Mechlorethamine (Nitrogen Mustard; Hn ₂)	May not prescribe	January 23, 2017: No change

Melphalan Hydrochloride	Alkylating Agents/ Nitrogen Mustards/ <i>Melphalan (Phenylalanine Mustard, L-Pam; L-Phenylalanine Mustard; L-Sarcylsin)</i>	May not prescribe	January 23, 2017: No change
Carmustine	Alkylating Agents/ Nitrosoureas/ <i>Carmustine (Bcnu)</i>	May not prescribe	January 23, 2017: No change
Lomustine (Ccnu)	Alkylating Agents/ Nitrosoureas	May not prescribe	January 23, 2017: No change
Streptozocin	Alkylating Agents/ Nitrosoureas	May not prescribe	January 23, 2017: No change
Dacarbazine (Dtic; Imidazole Carboxamide)	Alkylating Agents/ Triazenes	May not prescribe	January 23, 2017: No change
Mitoxantrone	Anthracenedione	May not prescribe	January 23, 2017: No change
Ado-Trastuzumab Emtansine	Antibody-Drug Conjugates	May not prescribe	January 23, 2017: No change
Brentuximab Vedotin	Antibody-Drug Conjugates	May not prescribe	January 23, 2017: No change
Methotrexate (For limited purpose of treating psoriasis and rheumatoid arthritis only)	Antimetabolites/ Folic Acid Antagonists/ <i>Methotrexate (Amethopterin; Mtx)</i>	In accordance with the SCA (see limitations on use)	January 23, 2017: No change
Pemetrexed	Antimetabolites/ Folic Acid Antagonists/	May not prescribe	January 23, 2017: No change
Pralatrexate	Antimetabolites/ Folic Acid Antagonists/	May not prescribe	January 23, 2017: No change
Allopurinol (Antineoplastic)	Antimetabolites/ Purine Analogs And Related Agents	May not prescribe	January 23, 2017: In accordance with the SCA
CLADRIBINE (2-Chlorodeoxyadenosine; Cda)	Antimetabolites/ Purine Analogs And Related Agents	May not prescribe	January 23, 2017: No change
Clofarabine	Antimetabolites/ Purine Analogs And Related Agents	May not prescribe	January 23, 2017: No change
Fludarabine Phosphate	Antimetabolites/ Purine Analogs And Related Agents	May not prescribe	January 23, 2017: No change
Mercaptopurine (6-Mercaptopurine; 6-Mp)	Antimetabolites/ Purine Analogs And Related Agents	May not prescribe	January 23, 2017: In accordance with the SCA

PENTOSTATIN (2'-Deoxycoformycin; DCF)	Antimetabolites/ Purine Analogs And Related Agents	May not prescribe	January 23, 2017: No change
Rasburicase	Antimetabolites/ Purine Analogs And Related Agents	May not prescribe	January 23, 2017: No change
Thioguanine (Tg; 6-Thioguanine)	Antimetabolites/ Purine Analogs And Related Agents	May not prescribe	January 23, 2017: No change
Capecitabine	Antimetabolites/ Pyrimidine Analogs	May not prescribe	January 23, 2017: No change
Cytarabine Conventional	Antimetabolites/ Pyrimidine Analogs	May not prescribe	January 23, 2017: No change
Cytarabine Liposomal	Antimetabolites/ Pyrimidine Analogs	May not prescribe	January 23, 2017: No change
Floxuridine	Antimetabolites/ Pyrimidine Analogs	May not prescribe	January 23, 2017: No change
Fluorouracil (5-Fluorouracil; 5-Fu)	Antimetabolites/ Pyrimidine Analogs	May not prescribe	January 23, 2017: In accordance with the SCA
Gemcitabine	Antimetabolites/ Pyrimidine Analogs	May not prescribe	January 23, 2017: No change
Trifluridine/Tipiracil	Antimetabolites/ Pyrimidine Analogs	May not prescribe	January 23, 2017: No change
Ixabepilone	Antimitotic Agents/ Epothilones	May not prescribe	January 23, 2017: No change
Eribulin Mesylate	Antimitotic Agents/ Halichondrin B Analog	May not prescribe	January 23, 2017: No change
Cabazitaxel	Antimitotic Agents/ Taxoids	May not prescribe	January 23, 2017: No change
Docetaxel	Antimitotic Agents/ Taxoids	May not prescribe	January 23, 2017: No change
Paclitaxel (Conventional)	Antimitotic Agents/ Taxoids	May not prescribe	January 23, 2017: No change
Paclitaxel Protein-Bound	Antimitotic Agents/ Taxoids	May not prescribe	January 23, 2017: No change
Vinblastine Sulfate (Vlb)	Antimitotic Agents/ Vinca Alkaloids	May not prescribe	January 23, 2017: No change

			change
Vincristine Sulfate (Vcr; Lcr)	Antimitotic Agents/ Vinca Alkaloids	May not prescribe	January 23, 2017: No change
Vincristine Sulfate Liposome	Antimitotic Agents/ Vinca Alkaloids	May not prescribe	January 23, 2017: No change
Vinorelbine Tartrate	Antimitotic Agents/ Vinca Alkaloids	May not prescribe	January 23, 2017: No change
Daunorubicin Citrate Liposomal	Antineoplastic Antibiotics/ Anthracyclines	May not prescribe	January 23, 2017: No change
Daunorubicin Hydrochloride	Antineoplastic Antibiotics/ Anthracyclines	May not prescribe	January 23, 2017: No change
Doxorubicin Hydrochloride Conventional	Antineoplastic Antibiotics/ Anthracyclines	May not prescribe	January 23, 2017: No change
Doxorubicin Hydrochloride, Liposomal (Pegylated Liposomal Doxorubicin)	Antineoplastic Antibiotics/ Anthracyclines	May not prescribe	January 23, 2017: No change
Epirubicin Hydrochloride	Antineoplastic Antibiotics/ Anthracyclines	May not prescribe	January 23, 2017: No change
Idarubicin Hydrochloride	Antineoplastic Antibiotics/ Anthracyclines	May not prescribe	January 23, 2017: No change
Valrubicin	Antineoplastic Antibiotics/ Anthracyclines	May not prescribe	January 23, 2017: No change
Bleomycin	Antineoplastic Antibiotics	May not prescribe	January 23, 2017: No change
Dactinomycin (Actinomycin D; Act)	Antineoplastic Antibiotics	May not prescribe	January 23, 2017: No change
Mitomycin (Mitomycin-C; Mtc)	Antineoplastic Antibiotics	May not prescribe	January 23, 2017: No change
Venetoclax	B-Cell Lymphoma-2 Inhibitor	May not prescribe	January 23, 2017: No change
Aldesleukin (Interleukin-2; Il-2)	Biological Response Modifiers	May not prescribe	January 23, 2017: No change
Bcg Live	Biological Response Modifiers	May not prescribe	January 23, 2017: In accordance with the SCA
Chemotherapy Regimens		May not prescribe	January 23, 2017: No change
Amifostine	Cytoprotective Agents	May not prescribe	January 23, 2017: No

			change
Dexrazoxane	Cytoprotective Agents	May not prescribe	January 23, 2017: No change
Leucovorin Calcium	Cytoprotective Agents/ Leucovorin Calcium (Folinic Acid; Citrovorum Factor)	May not prescribe	January 23, 2017: In accordance with the SCA
Levoleucovorin	Cytoprotective Agents	May not prescribe	January 23, 2017: In accordance with the SCA
Mesna	Cytoprotective Agents/ Mesna	May not prescribe	January 23, 2017: In accordance with the SCA
Azacitidine	Dna Demethylation Agents	May not prescribe	January 23, 2017: No change
Decitabine	Dna Demethylation Agents	May not prescribe	January 23, 2017: No change
Nelarabine	Dna Demethylation Agents	May not prescribe	January 23, 2017: No change
Irinotecan (Liposomal)	Dna Topoisomerase Inhibitors	May not prescribe	January 23, 2017: No change
Irinotecan Hydrochloride (Conventional)	Dna Topoisomerase Inhibitors	May not prescribe	January 23, 2017: No change
Topotecan Hydrochloride	Dna Topoisomerase Inhibitors/ Topotecan	May not prescribe	January 23, 2017: No change
Asparaginase (Erwinia)	Enzymes	May not prescribe	January 23, 2017: No change
Pegaspargase (Peg-L-Asparaginase)	Enzymes	May not prescribe	January 23, 2017: No change
Etoposide (Vp-16, Vp-16-213)	Epipodophyllotoxins/ Podophyllotoxin Derivatives/ <i>Etoposide (Vp-16, Vp-16-213)</i>	May not prescribe	January 23, 2017: No change
Etoposide Phosphate (Vp-16, Vp-16-213) Injection	Epipodophyllotoxins/ Podophyllotoxin Derivatives/ <i>Etoposide (Vp-16, Vp-16-213)</i>	May not prescribe	January 23, 2017: No change
Teniposide (Vm-26)	Epipodophyllotoxins/ Podophyllotoxin Derivatives	May not prescribe	January 23, 2017: No change
Belinostat	Histone Deacetylase Inhibitors	May not prescribe	January 23, 2017: No change

Panobinostat	Histone Deacetylase Inhibitors	May not prescribe	January 23, 2017: No change
Romidepsin	Histone Deacetylase Inhibitors	May not prescribe	January 23, 2017: No change
Vorinostat	Histone Deacetylase Inhibitors	May not prescribe	January 23, 2017: No change
Abiraterone Acetate	Hormones/ Antiandrogens	In accordance with the SCA	January 23, 2017: No change
Bicalutamide	Hormones/ Antiandrogens	In accordance with the SCA	January 23, 2017: No change
Enzalutamide	Hormones/ Antiandrogens	In accordance with the SCA	January 23, 2017: No change
Flutamide	Hormones/ Antiandrogens	In accordance with the SCA	January 23, 2017: No change
Nilutamide	Hormones/ Antiandrogens	In accordance with the SCA	January 23, 2017: No change
Fulvestrant	Hormones/ Antiestrogens	In accordance with the SCA	January 23, 2017: No change
Tamoxifen	Hormones/ Antiestrogens	In accordance with the SCA	January 23, 2017: No change
Toremifene	Hormones/ Antiestrogens	In accordance with the SCA	January 23, 2017: No change
Anastrozole	Hormones/ Aromatase Inhibitors	In accordance with the SCA	January 23, 2017: No change
Exemestane	Hormones/ Aromatase Inhibitors	In accordance with the SCA	January 23, 2017: No change
Letrozole	Hormones/ Aromatase Inhibitors	In accordance with the SCA	January 23, 2017: No change
Goserelin Acetate	Hormones/ Gonadotropin-Releasing Hormone Analog	In accordance with the SCA	January 23, 2017: No change
Histrelin Acetate	Hormones/ Gonadotropin-Releasing Hormone Analog	May not prescribe	January 23, 2017: No change
Leuprolide Acetate	Hormones/ Gonadotropin-Releasing Hormone Analog	In accordance with the SCA	January 23, 2017: No change
Leuprolide Acetate And	Hormones/	In accordance	January 23,

Norethindrone Acetate	Gonadotropin-Releasing Hormone Analog/ <i>Progestin Combination</i>	with the SCA	2017: No change
Triptorelin	Hormones/ Gonadotropin-Releasing Hormone Analog	May not prescribe	January 23, 2017: No change
Medroxyprogesterone Acetate (Cross-Reference)	Hormones/ Progestins (Cross-reference)	May not prescribe	January 23, 2017: No change
Megestrol Acetate (Cross-Reference)	Hormones/ Progestins (Cross-reference)	May not prescribe	January 23, 2017: No change
Temozolomide	Imidazotetrazine Derivatives	May not prescribe	January 23, 2017: No change
Dabrafenib	Kinase Inhibitors/ BRAF Inhibitors	May not prescribe	January 23, 2017: No change
Vemurafenib	Kinase Inhibitors/ BRAF Inhibitors	May not prescribe	January 23, 2017: No change
Palbociclib	Kinase Inhibitors/ Cyclin-Dependent Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Ruxolitinib	Kinase Inhibitors/ Janus-Associated Kinase Inhibitors	In accordance with the SCA	January 23, 2017: No change
Cobimetinib	Kinase Inhibitors/ MEK Inhibitors	May not prescribe	January 23, 2017: No change
Trametinib	Kinase Inhibitors/ MEK Inhibitors	May not prescribe	January 23, 2017: No change
Everolimus	Kinase Inhibitors/ mTOR Inhibitors	In accordance with the SCA	January 23, 2017: No change
Temsirolimus	Kinase Inhibitors/ mTOR Inhibitors	May not prescribe	January 23, 2017: No change
Regorafenib	Kinase Inhibitors/ Multikinase Inhibitor	May not prescribe	January 23, 2017: No change
Sorafenib	Kinase Inhibitors/ Multikinase Inhibitor	May not prescribe	January 23, 2017: No change
Idelalisib	Kinase Inhibitors/ Phosphatidylinositol 3-Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Afatinib	Kinase Inhibitors/ Tyrosine Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Alectinib	Kinase Inhibitors/	May not	January 23,

	Tyrosine Kinase Inhibitors	prescribe	2017: No change
Axitinib	Kinase Inhibitors/ Tyrosine Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Bosutinib	Kinase Inhibitors/ Tyrosine Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Cabozantinib	Kinase Inhibitors/ Tyrosine Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Ceritinib	Kinase Inhibitors/ Tyrosine Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Crizotinib	Kinase Inhibitors/ Tyrosine Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Dasatinib	Kinase Inhibitors/ Tyrosine Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Erlotinib	Kinase Inhibitors/ Tyrosine Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Gefitinib	Kinase Inhibitors/ Tyrosine Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Ibrutinib	Kinase Inhibitors/ Tyrosine Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Imatinib	Kinase Inhibitors/ Tyrosine Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Lapatinib	Kinase Inhibitors/ Tyrosine Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Lenvatinib	Kinase Inhibitors/ Tyrosine Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Nilotinib	Kinase Inhibitors/ Tyrosine Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Osimertinib	Kinase Inhibitors/ Tyrosine Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Pazopanib	Kinase Inhibitors/ Tyrosine Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Ponatinib	Kinase Inhibitors/ Tyrosine Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Sunitinib	Kinase Inhibitors/ Tyrosine Kinase Inhibitors	May not prescribe	January 23, 2017: No change
Vandetanib	Kinase Inhibitors/ Tyrosine Kinase Inhibitors	May not prescribe	January 23, 2017: No change

			change
Procarbazine Hydrochloride (N-Methylhydrazine; Mih)	Methylhydrazine Derivatives	May not prescribe	January 23, 2017: No change
Arsenic Trioxide	Miscellaneous Antineoplastics	May not prescribe	January 23, 2017: No change
MITOTANE (O,P'-DDD)	Miscellaneous Antineoplastics	May not prescribe	January 23, 2017: No change
Porfimer Sodium	Miscellaneous Antineoplastics	May not prescribe	January 23, 2017: No change
Sipuleucel-T	Miscellaneous Antineoplastics	May not prescribe	January 23, 2017: No change
Sonidegib	Miscellaneous Antineoplastics	May not prescribe	January 23, 2017: No change
Sterile Talc Powder	Miscellaneous Antineoplastics	May not prescribe	January 23, 2017: No change
Trabectedin	Miscellaneous Antineoplastics	May not prescribe	January 23, 2017: No change
Vismodegib	Miscellaneous Antineoplastics	May not prescribe	January 23, 2017: No change
Alemtuzumab	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change
Atezolizumab	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change
Bevacizumab	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change
Blinatumomab	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change
Cetuximab	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change
Daratumumab	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change
Dinutuximab	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change
Elotuzumab	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change
Ibritumomab Tiuxetan	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change

Ipilimumab	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change
Necitumumab	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change
Nivolumab	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change
Obinutuzumab	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change
Ofatumumab	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change
Olaratumab	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change
Panitumumab	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change
Pertuzumab	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change
Ramucirumab	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change
Rituximab	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change
Trastuzumab	Monoclonal Antibodies (Antineoplastic)	May not prescribe	January 23, 2017: No change
Talimogene Laherparepvec	Oncolytic Virus	May not prescribe	January 23, 2017: No change
Olaparib	Parp Enzymes Inhibitor	May not prescribe	January 23, 2017: No change
Carboplatin	Platinum Coordination Complex	May not prescribe	January 23, 2017: No change
Cisplatin (Cddp)	Platinum Coordination Complex	May not prescribe	January 23, 2017: No change
Oxaliplatin	Platinum Coordination Complex	May not prescribe	January 23, 2017: No change
Bortezomib	Proteasome Inhibitors	May not prescribe	January 23, 2017: No change
Carfilzomib	Proteasome Inhibitors	May not prescribe	January 23, 2017: No change
Ixazomib	Proteasome Inhibitors	May not	January 23,

		prescribe	2017: No change
Omacetaxine Mepesuccinate	Protein Synthesis Inhibitor	May not prescribe	January 23, 2017: No change
Radium Ra 223 Dichloride	Radiopharmaceuticals	May not prescribe	January 23, 2017: No change
Samarium Sm 153 Lexidronam	Radiopharmaceuticals	May not prescribe	January 23, 2017: No change
Sodium Iodide I 131 (Therapeutic)	Radiopharmaceuticals	May not prescribe	January 23, 2017: No change
Strontium-89 Chloride	Radiopharmaceuticals	May not prescribe	January 23, 2017: No change
Tretinoin (All-Trans-Retinoic Acid)	Retinoids (Antineoplastic)	May not prescribe	January 23, 2017: No change
Bexarotene (Oral)	Rexinoids (Oral)	May not prescribe	January 23, 2017: No change
Hydroxyurea	Substituted Ureas	May not prescribe	January 23, 2017: In accordance with the SCA
Ziv-Aflibercept	Vascular Endothelial Growth Factor	May not prescribe	January 23, 2017: No change